IL-26: A Potential Drug Target for Cancer and Fibrosis (G55801)

Target Name: IL26

NCBI ID: G55801

IL26

IL-26: A Potential Drug Target for Cancer and Fibrosis

IL-26 (Interleukin-26) is a cytokine that plays a crucial role in the immune response and inflammation. It is a protein that is expressed in a variety of tissues throughout the body, including the lungs, heart, kidneys, and intestines. IL-26 is involved in the regulation of an immune response, cell proliferation, and fibrosis.

One of the things that makes IL-26 an attractive drug target is its role in the development and progression of a variety of diseases, including cancer, autoimmune disorders, and chronic obstructive pulmonary disease (COPD). It is also involved in the regulation of inflammation, which can make it a useful target for treatments aimed at reducing inflammation and improving immune function.

IL-26 is a cytokine that is involved in the immune response and has been shown to play a role in a variety of diseases.

One of the things that makes IL-26 an attractive drug target is its role in the development and progression of cancer. Studies have shown that high levels of IL-26 are associated with an increased risk of the development of cancer. IL-26 has also been shown to promote the growth and survival of cancer cells, which makes it a potential target for cancer treatments.

In addition to its role in cancer, IL-26 is also involved in the development and progression of autoimmune disorders. These disorders occur when the immune system attacks the body's own tissues, leading to inflammation and pain. IL-26 is thought to play a role in the regulation of the immune response and has been shown to contribute to the development and progression of autoimmune disorders.

IL-26 is also involved in the regulation of fibrosis, which is the thickening of connective tissue that can occur in a variety of conditions, including cancer, heart disease, and COPD. Fibrosis can lead to the loss of flexibility and function in the body's tissues, which can have serious consequences. IL-26 has been shown to play a role in the regulation of fibrosis and has been shown to be a potential target for treatments aimed at reducing fibrosis.

In addition to its role in the immune response and fibrosis, IL-26 is also involved in the regulation of inflammation. Inflammation is a natural response of the immune system, but chronic inflammation can contribute to a variety of diseases, including cancer and autoimmune disorders. IL-26 is thought to play a role in the regulation of inflammation and has been shown to contribute to the development and progression of these conditions.

Overall, IL-26 is a protein that is involved in a variety of processes throughout the body. It is a potential drug target due to its role in the development and progression of cancer, autoimmune disorders, and fibrosis, as well as its involvement in the regulation of inflammation. Further research is needed to fully understand the role of IL-26 in these processes and to develop effective treatments.

Protein Name: Interleukin 26

Functions: May play a role in local mechanisms of mucosal immunity and seems to have a pro-inflammatory function. May play a role in inflammatory bowel disease. Activates STAT1 and STAT3, MAPK1/3 (ERK1/2), JUN and AKT. Induces expression of SOCS3, TNF-alpha and IL-8, secretion of IL-8 and IL-10 and surface expression of ICAM1. Decreases proliferation of intestinal epithelial cells. Is inhibited by heparin

The "IL26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets